Product Images Duloxetine Delayed-release

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Duloxetine Delayed-release NDC 67046-679 by Contract Pharmacy Services-pa, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

D3 - Duloxetine 30mg 691

D3 - Duloxetine 30mg 691

DULOXETINE DR is a medication that comes in a bottle containing 30 capsules, each capsule has a dosage of 30mg. The lot number is not provided, but the expiry date is 12/31/2020. This medication is sold only on a doctor's prescription. The manufacturer is Breckenridge and the standard global trade identification number is GTINDD387046891302. The pill ID is B747. Please refer to the accompanying literature for dosage. The medication should be stored at a temperature range of 15-30°C (50-85°F). Each capsule contains 33.7mg of duloxetine hydrochloride USP equivalent to 30mg duloxetine. The medication is packaged by Contract Pharmacy Services in Pennsylvania and the National Drug Code (NDC) is 67045-391-30.*

D6 - Duloxetine 60mg 679

D6 - Duloxetine 60mg 679

This is a medication called Duloxetine available in the form of capsules with 60mg strength in a pack of 30. The medicine should be stored at a temperature between 15-30°C (58-86°F). It contains Duloxetine Hydrochloride USP equivalent to 67.3mg. For dosage information, you can refer to the accompanying literature. It is an RX-only medicine that can be purchased with a proper prescription. The information contains the Lot, pill ID, Sin, GTIN, and other details. Expiration details can be found in the text.*

Chemical Structure - duloxetine 01

Chemical Structure - duloxetine 01

Figure 1 - duloxetine 02

Figure 1 - duloxetine 02

The text represents a graph showing the proportion of patients who had a relapse based on the treatment they received (placebo or duloxetine) and the time (in days) from randomization to relapse.*

Figure 2 - duloxetine 03

Figure 2 - duloxetine 03

The given text represents a chart showing the proportion of patients who experienced relapse over the course of time after being randomized to either Placebo or Duloxetine treatment. It shows the proportion of patients experiencing relapse decreasing over time in both treatment groups, with Duloxetine showing a lower proportion of relapses compared to Placebo.*

Figure 3 - duloxetine 04

Figure 3 - duloxetine 04

This appears to be a graph or chart showing the percentage of patients who improved and the percentage of improvement in pain from baseline. Without more context or labels it is difficult to provide a more specific description.*

Figure 4 - duloxetine 05

Figure 4 - duloxetine 05

Figure 7 - duloxetine 06

Figure 7 - duloxetine 06

The text shows a chart of the percentage of patients improved with a placebo and Duloxetine at varying doses. It also includes a graph measuring the percent improvement in pain from baseline.*

Figure 8 - duloxetine 07

Figure 8 - duloxetine 07

This is a graph displaying the percentage of patients' improvement in pain from baseline (BOCF) after taking a placebo or DUL 60 mg once daily medication. The improvement rates are shown on the y-axis and range from 0% to 100%. The x-axis shows the different treatment options. It appears that the DUL 60 mg once daily medication resulted in a higher rate of improvement compared to the placebo, with a 100% improvement rate noted.*

Figure 9 - duloxetine 08

Figure 9 - duloxetine 08

The text presents a chart comparing the percentage of patients improved in pain from baseline for a placebo group and a group taking DUL 60/120 mg once daily. The chart also includes a graph illustrating the percent improvement in pain from baseline (BOCF) for the different treatment groups.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.